MGF (Mechano Growth Factor / IGF-1Ec splice variant)
Splice variant of IGF-1 with a unique E-domain peptide expressed in response to mechanical loading.
At a glance
What it is: Splice variant of IGF-1 with a unique E-domain peptide expressed in response to mechanical loading..
Primary research applications:
- Skeletal muscle research
- Recovery and regeneration research
Editorial summary: MGF is a fascinating biology — a tissue-specific splice variant of IGF-1 generated in response to mechanical stress. Synthetic MGF peptides used in research and online have a much smaller evidence base than the underlying biology. Most user-facing claims rest on extrapolation from the splice variant's role in muscle rather than controlled human studies of injected analogs.
- Class / structure
- Splice variant of IGF-1 (IGF-1Ec); the unique E-domain is the basis for synthetic MGF peptides
- Half-life
- Very short — minutes (PEG-MGF analogs extend duration)
- First described
- 1990s (Goldspink group)
- Regulatory status
- Not FDA-approved; research-grade only
What is MGF?
MGF refers both to the IGF-1Ec splice variant produced by stretched muscle and to synthetic peptides corresponding to the unique E-domain region used in research and the peptide marketplace.
Discovery and development
The mechano growth factor concept was developed primarily by Geoffrey Goldspink and colleagues, who showed that mechanical stretch of skeletal muscle induces alternative splicing of the IGF-1 gene to produce a splice variant (IGF-1Ec in humans) with a distinct E-domain. The hypothesis: this splice variant has a separate regenerative role in response to mechanical loading.[1]
Mechanism of action
The Goldspink-group hypothesis is that the E-domain peptide acts on satellite cells (muscle stem cells) to promote their activation and proliferation in response to mechanical loading or injury, complementing the effects of mature IGF-1 itself.[1]
Pharmacokinetics
Native MGF peptides are highly unstable in plasma. PEGylated MGF analogs (PEG-MGF) extend the half-life but remain investigational.
What the research shows
The peer-reviewed literature on MGF is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| MGF is upregulated by exercise and injury in humans | Native splice-variant biology | Supported |
| Synthetic MGF peptide injections build muscle in humans | No controlled human trials | Uncertain |
| Produces effects equivalent to IGF-1 | Different biology; not interchangeable | Unsupported |
Reported user experiences
How the research describes administration
User communities describe subcutaneous and intramuscular use of synthetic MGF or PEG-MGF; no FDA-approved formulations exist.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
The native MGF / IGF-1Ec biology is genuinely interesting — a clean illustration of tissue-specific alternative splicing in response to mechanical loading. Synthetic MGF peptide use is a different proposition: built on extrapolation from that biology, with limited controlled human evidence and significant marketplace heterogeneity. The two should not be conflated in evaluating claims.
Frequently asked questions
Is MGF the same as IGF-1?
No. IGF-1 and IGF-1Ec (the parent of MGF) are alternative splice products of the IGF-1 gene with different mature forms and different downstream activities.
Is PEG-MGF different from MGF?
PEG-MGF is a pegylated version designed to extend the very short native half-life. The fundamental peptide sequence is the same; pegylation changes the pharmacokinetics.
References
- Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology. 2005;20:232-238. https://pubmed.ncbi.nlm.nih.gov/16024511/
- Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil. 1996;17(4):487-495. https://pubmed.ncbi.nlm.nih.gov/8884603/
- Janssen JA, Hofland LJ. Editorial: Critical reflections on the new IGF-I literature regarding mechano growth factor. Front Endocrinol (Lausanne). 2018;9:498. (Critical review of MGF translational claims.) https://pubmed.ncbi.nlm.nih.gov/30214428/